Cargando…
Promise and Implementation of Proteomic Prostate Cancer Biomarkers
Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers al...
Autores principales: | Latosinska, Agnieszka, Frantzi, Maria, Merseburger, Axel S., Mischak, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174350/ https://www.ncbi.nlm.nih.gov/pubmed/30158500 http://dx.doi.org/10.3390/diagnostics8030057 |
Ejemplares similares
-
Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
por: Frantzi, Maria, et al.
Publicado: (2020) -
Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of –omics findings
por: Latosinska, Agnieszka, et al.
Publicado: (2016) -
Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation
por: Latosinska, Agnieszka, et al.
Publicado: (2020) -
CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
por: Frantzi, Maria, et al.
Publicado: (2019) -
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
por: Frantzi, Maria, et al.
Publicado: (2014)